Hut 8 Corp vs ResMed Inc. — how do they compare? Hut 8 Corp trades at $91.25 (market cap $10.94B), while ResMed Inc. trades at $224.81 (market cap $32.61B). The key difference: ResMed Inc. is far larger — about 3× Hut 8 Corp's market cap, and ResMed Inc. pays a 1.17% dividend while Hut 8 Corp pays none. Which is the better fit depends on your goals.
| HUT | RMD | |
|---|---|---|
Market Cap | $10.94B | $32.61B |
Sector | Technology | Health |
52-Week High | $133.02 | $293.73 |
52-Week Low | $21.37 | $182.82 |
Enterprise Value | $18.38B | $31.97B |
Dividend Yield | — | 1.17% |
Signals from Pluang's Aura AI — not financial advice
HUT trades at $93.91, up 9.63% today amid a broader neocloud stock rally. The stock shows bearish technical signals with support at $87 and resistance at $92. Fundamentally, revenue grew 81% year-over-year in Q2 2026 to $74 million, but net losses persist with a -188.59% margin. The company is transitioning to an AI data center focus, securing $26.6 billion in contracted backlog and $7.5 billion in project financing.
Outlook is polarized: strong analyst buy consensus (93.75%) and a $165.11 price target reflect optimism in AI infrastructure growth, but high valuation ratios and persistent losses pose risks. Execution on Beacon Point commercialization and debt management are critical for upside.
ResMed (RMD) trades at $221.22, up 0.53% with a bullish technical signal and strong fundamental performance. The company delivered four consecutive quarterly earnings beats, with Q4 2026 EPS of $2.95 beating expectations by 2.1%. Revenue grew 9% year-over-year to $1.5 billion, while maintaining robust profitability with 61.1% gross margins and 26.9% net income margins. Recent strategic moves include the $490 million sale of MatrixCare to focus on core sleep and respiratory care markets.
The stock presents a compelling growth story with consistent execution, though near-term headwinds from weak 2027 revenue guidance create uncertainty. Analyst consensus targets $235.00 (6.2% upside) with 40% buy ratings. Key risks include ventilator sales suspension, cost pressures, and competitive threats in the medical device space. The company's strong cash flow generation and shareholder returns ($1.0 billion in 2026) support long-term value creation.
Trailing returns across standard periods
Latest headlines on both assets
Hut 8 is one of North America's largest digital asset miners and infrastructure providers. It operates diversified data centers supporting Bitcoin mining and high-performance computing (HPC) for AI.
Read more on HUT →ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →